Research summary
Baseline C-reactive protein and LDL cholesterol were measured in 27,939 apparently healthy American women followed for a mean of eight years for cardiovascular events; the analysis directly compared the two markers' predictive value for myocardial infarction, ischemic stroke, coronary revascularization and cardiovascular death [1]. Among 14,719 apparently healthy women followed eight years, with 24% meeting metabolic-syndrome criteria at entry, CRP, the metabolic syndrome and incident cardiovascular events were jointly modeled to quantify CRP's contribution above the syndrome itself [2]. A 1987 textbook on epidemiology in medicine framed the field as the most direct method for studying causes of human disease and described the growing need for team-based design and data collection [3]. The Women's Health Study randomized 39,876 initially healthy women aged 45 or older to 100 mg alternate-day aspirin or placebo and followed them for 10 years; the aspirin group recorded 477 major cardiovascular events versus 522 on placebo, a nonsignificant reduction [4]. The Reynolds Risk Score was developed and validated for women: 35 traditional and novel risk factors were assessed among 24,558 initially healthy US women aged 45 or older followed for a median 10.2 years, with derivation in a random two-thirds and validation in the remainder [5]. Baseline CRP was measured in 122 women with incident cardiovascular events and 244 age- and smoking-matched controls from the Women's Health Study; women with future events had higher baseline CRP, and those in the top quartile had a roughly fivefold increase in vascular event risk [6]. Triglyceride levels measured in 26,509 initially healthy women (20,118 fasting, 6,391 nonfasting) followed for a median 11.4 years compared the predictive value of fasting versus nonfasting triglycerides for future cardiovascular events [7]. The VITAL trial tested 2,000 IU/day vitamin D3 and 1 g/day marine omega-3 against placebo in men aged 50+ and women aged 55+ for prevention of invasive cancer and major cardiovascular events [8]. SCORE2 derived sex-specific competing-risk-adjusted 10-year CVD risk models from 677,684 individuals in 45 cohorts across 13 countries (30,121 events), calibrated to four European risk regions using age, smoking, systolic blood pressure and total/HDL cholesterol [9].
Recent publications
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsDOI
- AtherosclerosisDOI
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsDOI
- Epidemiology in Medicine
- A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in WomenDOI
- Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in WomenDOI
- Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy WomenDOI
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenDOI
- Vitamin D Supplements and Prevention of Cancer and Cardiovascular DiseaseDOI
- SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in EuropeDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Julie E. Buring 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0003-2648-8692
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Nagoya University faculty directory). Last refreshed 2026-05. Report incorrect information.